转基因：美国认错了。

• maintain high standards that are based on the best available science and that deliver appropriate health and environmental protection;
  
• establish transparent， coordinated， predictable， and efficient regulatory practices across agencies with overlapping jurisdiction; and
  
• promote public confidence in the oversight of the products of biotechnology through clear and transparent public engagement.
  
  

（a） update the CF to clarify the current roles and responsibilities of the agencies that regulate the products of biotechnology， after input from the public， by clarifying:

（i） which biotechnology product areas are within the authority and responsibility of each agency;

（ii） the roles that each agency plays for different product areas， particularly for those product areas that fall within the responsibility of multiple agencies， and how those roles relate to each other in the course of a regulatory assessment;

（iii） a standard mechanism for communication and， as appropriate， coordination among agencies， while they perform their respective regulatory functions， and for identifying agency designees responsible for this coordination function; and

（iv） the mechanism and timeline for regularly reviewing， and updating as appropriate， the CF to minimize delays， support innovation， protect health and the environment and promote the public trust in the regulatory systems for biotechnology products; and

（b） develop a long-term strategy to ensure that the Federal regulatory system is equipped to assess efficiently the risks， if any， associated with future products of biotechnology while supporting innovation， protecting health and the environment， maintaining public confidence in the regulatory process， increasing transparency and predictability， and reducing unnecessary costs and burdens by:

（i） developing a plan for periodic formal horizon-scanning assessments of new biotechnology products to ensure that regulatory agencies are prepared for future products well before they reach the regulatory system;

（ii） working with other Federal agencies， as appropriate， to develop a coordinated and goal-oriented plan for supporting the science that informs regulatory activities with regard to the assessment of biotechnology products， and to reflect these priorities in agency budget submissions starting with the fiscal year （FY） 2017 budget;

（iii） ensuring that product evaluations are risk-based and grounded in the best science available， including regularly adjusting regulatory activities based on experience with specific products and the environments into which those products have been introduced;

（iv） establishing a timetable and mechanisms to work with stakeholders to identify impediments to innovation， focusing on building new， and augmenting existing， stakeholder collaborations to inform efforts， increase transparency， streamline processes， reduce costs and response times， and ensure the protection of health and the environment;

（v） coordinating the development of tools and mechanisms for assisting small businesses developing biotechnology products to navigate the regulatory system;

（vi） identifying changes to authorities， regulations， and policies， if any， that could improve agencies’ abilities to assess expeditiously the potential impacts and risks arising from future products of biotechnology and to ensure the transparency， predictability， and efficiency of regulatory oversight for such products;

（vii） initiating development of a modernized， user-friendly set of tools for presenting the regulatory agencies’ authorities， practices， and bases for decision making for the regulation of biotechnology products to the public， including digital services to improve the interactions between the FDA， EPA， USDA， the general public， and product developers and updating these tools and practices regularly to ensure optimal transparency; and

（viii） proactively engaging with the public to discuss how the Federal government uses a risk-based， scientifically sound approach to regulating the products of biotechnology， and clearly communicating to the public which types of products are regulated， which types of products are not regulated， and why.